Lugar de publicación

• The molecular basis for peptide-based antimalarial vaccine development targeting erythrocyte invasion by P. falciparum.  534:86-93. 2021
• Malaria: Paving the way to developing peptide-based vaccines against invasion in infectious diseases.  527:1021-1026. 2020
• Discovering key residues of dengue virus NS2b-NS3-protease.  492:631-642. 2017
• Structural analysis of owl monkey MHC-DR shows that fully-protective malaria vaccine components can be readily used in humans.  491:1062-1069. 2017
• Critical role of HLA-DRβ* binding peptides' peripheral flanking residues in fully-protective malaria vaccine development.  489:339-345. 2017
• The role of pi-interactions and hydrogen bonds in fully protective synthetic malaria vaccine development.  484:501-507. 2017
• TCR-contacting residues orientation and HLA-DRβ* binding preference determine long-lasting protective immunity against malaria.  477:654-660. 2016
• Protecting capacity against malaria of chemically defined tetramer forms based on the Plasmodium falciparum apical sushi protein as potential vaccine components.  451:15-23. 2014
• Phi (Φ) and psi (Ψ) angles involved in malarial peptide bonds determine sterile protective immunity.  429:75-80. 2012
• The high immunogenicity induced by modified sporozoites' malarial peptides depends on their phi (ϕ) and psi (ψ) angles.  429:81-86. 2012
• 3D structure and immunogenicity of Plasmodium falciparum sporozoite induced associated protein peptides as components of fully-protective anti-malarial vaccine.  416:349-355. 2011
• A Maurer's cleft-associated Plasmodium falciparum membraneassociated histidine-rich protein peptide specifically interacts with the erythrocyte membrane.  122-126. 2009
• Structural characteristics of immunogenic liver-stage antigens derived from P. falciparum malarial proteins..  455-460. 2009
• Identification and evaluation of universal epitopes in Plasmodium vivax Duffy binding protein.  377:1279-1283. 2008
• The Plasmodium vivax Pv41 surface protein.  377:1113-1117. 2008
• Characterisation of the Plasmodium vivax Pv38 antigen.  376:326-330. 2008
• Functional characterization of Mycobacterium tuberculosis Rv2969c membrane protein.  372:935-940. 2008
• HLA-DR allele reading register shifting is associated with immunity induced by SERA peptide analogues.  372:114-120. 2008
• Monosaccharides modulate HCV E2 protein-derived peptide biological properties.  355:409-418. 2007
• Cloning, expression, and characterisation of a Plasmodium vivax MSP7 family merozoite surface protein.  351:639-644. 2006
• Plasmodium falciparum TryThrA antigen synthetic peptides block in vitro merozoite invasion to erythrocytes.  339:888-896. 2006
• Changing ABRA protein peptide to fit into the HLA-DRbeta1*0301 molecule renders it protection-inducing.  322:119-125. 2004
• Identifying Plasmodium falciparum EBA-175 homologue sequences that specifically bind to human erythrocytes.  321:835-44. 2004
• MAEBL Plasmodium falciparum protein peptides bind specifically to erythrocytes and inhibit in vitro merozoite invasion.  315:319-29. 2004
• Shortening and modifying the 1513 MSP-1 peptide’s α-helical region induces protection against malaria.  315:418-427. 2004
• Identifying gp85- regions involved in Epstein- Barr virus binding to Blymphocytes..  319:221-229. 2004